$AXON

Brooks Cameron sold $621K of AXON

Brooks Cameron (CHIEF REVENUE OFFICER) sold 1,242 shares of AXON ENTERPRISE, INC. (AXON) at $500.00 ($0.62M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brooks Cameron
Published Jun 8, 2026, 8:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AXON
Neutral
high confidence
Mentioned
$AXON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not, by itself, change AXON’s operating outlook or provide new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 structure reduces interpretive weight.

03

What to watch

The article provides only the sale details; it does not indicate whether other insiders bought, whether the plan size is increasing, or whether there were concurrent corporate catalysts.

Relevance 4/10Novelty 2/10Timing: Filed June 8, covering a sale executed June 4.

Background

This is an SEC Form 4 insider transaction disclosure from AXON, reported via SEC EDGAR.

Company-level read

Ticker impact

$AXONNeutralHigh confidence
Context

Brooks Cameron (Chief Revenue Officer) filed an open-market sale of 1,242 AXON shares at $500/share under a 10b5-1 plan.

Expected impact

Likely minimal; any reaction should be muted unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

No direct sector read-through; this is an individual insider transaction without disclosed business developments.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may watch for clustering of sales around specific windows.

Key entities

  • AXON ENTERPRISE, INC.

    Company whose shares were sold by an insider under a 10b5-1 plan.

  • Brooks Cameron

    Chief Revenue Officer who sold 1,242 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.